# Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors

> **NCT02534506** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 18 (estimated)

## Conditions studied

- Malignant Tumors

## Interventions

- **DRUG:** Urelumab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT02534506
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-06
- **Primary completion:** 2016-11-11
- **Final completion:** 2016-11-11
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2020-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02534506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02534506, "Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02534506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*